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Summary Exposure to aromatic amines is considered a major risk factor for the development of bladder cancer. In this study, we have
analysed the pattern of point mutations in several tumour genes in 21 cases of bladder cancer arising among western European workers
exposed to aromatic amines in an attempt to determine whetherthis exposure may be associated with a unique spectrum of mutations. Of the
four genes analysed (p53, p16mTs1, p21WAF1 and H-ras), only p53 showed a high frequency of mutations (in 8 out of 21 cases, 38%). Two
mutations were found in p16, one in H-ras and none in p21 exon 3. All mutations were at G:C base pairs, mostly at non-CpG residues. This
spectrum of mutations, which is highly suggestive of an involvement of exogenous carcinogens, is however identical to the spectrum of p53
mutations detected in bladder cancers of the general population. In exposed workers, p53 mutations were associated with tumour grade and
with high occupational and tobacco exposure. Taken together, our data suggest that the same carcinogens may be responsible for the
development of bladder cancers in workers exposed to aromatic amines and in the general population.
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Bladder cancer is the eighth most common cancer worldwide in
men and is associated with several risk factors, the contributions of
which vary greatly in different countries and populations (Parkin
et al, 1993). Risk factors for bladder cancer include tobacco
smoking, exposure to certain therapeutic drugs, such as phenace-
tine, chronic infection by the parasite Schistosoma haematobium
and exposure to aromatic amines (IARC, 1987, 1994).
Epidemiological studies have clearly shown that an increase in
incidence ofbladder cancer is observed in humans occupationally
exposed to f-naphthylamine, benzidine and 4-aminobiphenyl.
Experimental studies in rodents and dogs have also shown
that these agents are carcinogenic. Thus, there is clear evidence
that these aromatic amines are potent bladder carcinogens
(IARC, 1972).
Aromatic amines are involved in many industrial processes,
such as chemical dye production, plastic and rubber manufac-
turing and textile and leather industries. Bladder cancer was recog-
nized as early as 1895 among workers of the dye manufacturing
industry. Although the recognition of this association has led to
dramatic changes in working practices and industrial processes
over the past 40 years, recent studies indicate that workers in the
dyestuff production still experience a 2.6-4.6 relative risk of
bladder cancer, even after adjustment for age and smoking (Boyko
et al, 1985; La Vecchia, 1990).
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Another potentially important source of exposure to aromatic
amines is tobacco smoking. In addition to a number of well-
characterized human carcinogens, tobacco smoke contains 4-amino-
biphenyl (4-ABP) and 2-naphthylamine (P-naphthylamine, 2-NA).
In developed countries, between 40% and 70% of bladder cancers
occurring in men are attributable to tobacco exposure and it has been
proposed that aromatic amines may be responsible for the excess of
bladder cancers observed in smokers (Pisani et al, 1993). Moreover,
the analysis of DNA adducts in urothelial cells of smokers indicates
that DNAdamage may be due to aromatic amines ratherthan to other
tobacco carcinogens, such as benzo(a)pyrene (Vineis et al, 1996).
In 1995, we published a preliminary report indicating that the
p53 gene was mutated with a frequency of 30% in a group of 12
bladder cancers occurring in workers who had been occupationally
exposed to aromatic amines in western Europe (Esteve et al,
1995). The results reported here are an extension of the prelimi-
nary study and include 21 tumours from patients for whom data on
occupational exposure and cigarette smoking were available. In
addition to p53, we have analysed other genes that may be the
targets of chemical carcinogens, such as H-ras and the cyclin
kinase inhibitorpl6.
Point mutation in the p53 tumour-suppressor gene is a common
genetic alteration in human cancer. Mutations usually occur at more
than 150 distinct codons within the central portion ofthe gene, and
the nature and location of these mutations can be informative in
assessing the role of putative carcinogenic agents (Hainaut et al,
1997). In bladder cancers, thep53 gene is mutated with a frequency
that varies from 18% to 50% (Williamson et al, 1994; Vet et al,
1994; Taylor et al, 1996), with one report describing a frequency of
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62% in the endemic area of 'black foot disease' in Taiwan, aregion
at high risk for bladder cancer (Shibata et al, 1994).
Deletions at 9p2l-22 are frequent in bladder cancers and are
often detectable in low-grade tumours, suggesting that one (or
several) tumour-suppressor genes located in this region may play an
important role in the genesis of bladder cancer (Southgate et al,
1995; Williamson et al, 1995). One candidate gene at this locus is
pl6, which encodes an inhibitor of cyclin-dependent kinases 4 and
6, active atthe G1/S transition ofthe cell cycle. In mouse and rat, the
Ha-ras gene is often activated by mutation in liver tumours induced
by exposure to benzidine, with the most frequently detected muta-
tion being a C:G to A:T transversion at the first nucleotide ofcodon
61. The cyclin kinase inhibitor p21WAFI is rarely mutated in human
cancers but is transcriptionally activated by p53 and is responsible
for cell cycle arrest at the G,/S border (Levine, 1997).
Our results indicate that only p53 is frequently mutated in
workers exposed to aromatic amines. The frequency of mutations
increases with tumour grade, but the spectrum ofp53 mutations in
exposed workers is similar to the one in the general population.
We also show that the frequency ofp53 mutations increases with
high occupational exposure and tobacco consumption. These
results are compatible with those reported by Taylor et al (1996) in
a cohort of exposed workers in North America.
MATERIAL AND METHODS
Tumour samples
Twenty-one bladder cancer cases were identified from a cohort
of dyestuff manufacturing workers employed at Bayer A-G,
Leverkusen, Germany. All tumours were archived at the Institute
of Biology Monitoring, Arztliche Abteilung, Bayer AG. Tissues
were fixed in formalin and embedded in paraffin. Data on expo-
sure to aromatic amines are based on the occupational history of
each individual. Data on smoking history are from the company
medical records and are based on self-reported information via
questionnaires (Table 1).
Immunohistochemical analysis of p53 and p21 WAFi
proteins
Immunohistochemical detection of p53 protein was performed
using the avidin-biotin-peroxidase complex (ABC) method (Hsu
et al, 1981). Sections were deparaffinized, inactivated for endo-
genous peroxidase activity and incubated with normal serum to
block cross-reactivity before incubating overnight at 4°C with the
p53 polyclonal antibody CM-I (1:100). Immunostaining with the
p21 monoclonal antibody Ab-1 (1:300, Oncogene Science) was
performed using the same procedure, except that sections were
microwaved in citrate buffer to unmask the epitopes of the protein
before incubation with normal serum. The immunoreactivity was
classified into five categories by estimating the percentage ofposi-
tive nuclei in the tumour tissue: -, no immunoreactivity; +, <5%;
++, 5-20%; +++ 20-50%; ++++, >50%.
Detection of mutations in p53, H-ras, p16 and p21
Haematoxylin- and eosin-stained sections (5 jm) were used to
identify neoplastic regions to be analysed for gene alterations, and
tumour areas were microdissected from 10-,um matched, unstained
Table 1 Distribution of bladder cancer cases according to occupational exposure, smoking history and tumour grade
Occupational exposure Smoking
ID Benzidine 2-NA 4APB Azobenzol Age at first exposure Duration Pack/year Duration Years
(years) (years) (years) quit
Grade 1
6/1 + 45 14 27.3 22
12/1 + + 43 1 182.5 35 2
14/1 + 24 32 NS
24/1 + + 19 31 91.25 55
27/1 + 43 11 228.72 28 11
Grade 2
8/1 + + 44 20 NS
11/1 + + 24 25 NS
17/1 + 37 4 136.87 38
19/1 + 31 28 319.37 60
21/1 + + 14 49 273.75 33 11
23/1 + NA 182.5 41
28/1 + 18 2 NS
30/1 + 41 16 182.5 40
31/1 + 33 27 182.5 9 10
Grade 3
1/1-2 + 37 13 146 30
16/1 + + 24 18 200.75 67
20/1 + + 32 5 182.5 31
22/1 + 32 24 365 40
25/1 + 56 7 NS
26/1 + 25 ? NS
29/1 + + 31 29 NS
NS, non-smoker; NA, not applicable.
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Table 2 Distribution of p53and p16MTS1 mutations and of p2lWAFl expression by tumour grade
Case no. p53Analysis p16Mutation p21WAF1 Expression
IHCa Codon Mutation AA change Codon Mutation AA change IHC"
Grade 1
6/1 _
12/1 - ++++
14/1 - 28 GTG>ATG Val>Met +
24/1 - NA
27/1 -+
Grade 2
8/1 ++
11/1 +
17/1 ++
19/1 ++ ++
21/1 - 231 ACC>ACT Silent NA
23/1 ++
28/1b
30/1 + 276 GCC>ACC Ala>Thr ++
31/1 +++ 192 CAG>AAG Gln>Lys 148d GCG>ACG Ala>Thr
214 CAT>TAT His-Tyr
Grade 3
1/1-2 ++++ 273 CGT>CTT Arg>Leu
16/1 +C 117 GGG>GAG Gly>Glu ++
20/1 .... 273 CGT>CTT Arg>Leu ++
22/1 .... 242 TGT>TAC Cys>Tyr ++
25/1 +++ NA
26/1 110 TGG>TGA Trp>stop +
29/1 - 282 CGG>TGG Arg>Trp +
alHC, immunohisto chemistry scoring is defined in the text. bThe patient has a homozygous polymorphism at codon 213 (CGA>CGG). cThe tumour shows
staining only in the cytoplasm. dPolymorphism. NA, tumour tissue not available.
tissue sections. Extraction of DNA from microdissected regions
was performed as described previously (Esteve et al, 1993, 1995).
Exons 5-8 (in some cases also 4 and 9) of the p53 gene were
amplified using a nested polymerase chain reaction (PCR) strategy
with the primers described by Lehman et al (1991, 1993). PCR
products were subjected to direct sequencing after conversion to
single-stranded DNA by (a) asymmetric PCR or (b)using biotinyl-
ated primers and streptavidin-coated magnetic beads. For H-ras,
exons 1 and 2, covering codons 12, 13 and 61, were amplified by
PCR (Lehman et al, 1991) and the PCR products were analysed by
sequencing. Forp16, exons 1 and 2 were analysed using the asym-
metric approach and direct sequencing as described in Esteve et al
(1996). For p21, exon 3 (not exons 2 and 3 because of method-
ological difficulties) was amplified with GC-clamped primers and
the products were analysed by constant denaturing gradient gel
electrophoresis (CDGE) (B0rresen et al, 1996). All mutations were
confirmed by repeating all steps in the procedure.
RESULTS
Study subjects
The tumours analysed here were all transitional cell carcinomas,
grade 1-3, occurring in 21 male workers exposed to aromatic
amines. During their employment, most patients were exposed to
multiple aromatic amine derivatives, including benzidine (15
patients), 4-amino-biphenyl (4-ABP, three patients), 2-naphhtyl-
amine (2-NA, ten patients) and azobenzol (one patient). Age at
first exposure varied from 14 to 56 years, and time of exposure
Table 3 Distribution of p53 mutations by exposure and tumour gradea
Cases with p53 mutations (total number of cases)
Occupational exposure Exposure to tobacco
Grade Low High Non-smoker Heavy smoker
Total 2 (7) 5 (9) 1 (7) 5 (9)
1 0 (3) 0 (2) 0 (1) 0 (2)
2 1 (2) 2 (4) 0 (3) 2 (4)
3 1 (2) 3 (3) 1 (3) 3 (3)
aPatients were classified in two groups corresponding to low and high
exposure to either aromatic amines (occupational exposure) or smoking
(exposure to tobacco). Criteria for distinction between low and high exposure
are defined in text.
ranged from 1 year (patient 12/1) to 49 years (patient 21/1). The
period of exposure covered years 1927-81. Of these 21 patients,
ten had a continuous cigarette-smoking history at the time of the
diagnosis, four were ex-smokers and seven reported themselves as
non-smokers (Table 1).
Analysis of p53 mutations
p53 exons 4-9 (including flanking intronic splicing sites) were
first analysed for the presence of mutations using PCR and direct
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Figure 1 Results of sequence analyses of the p164T~s1 gene in two of the
bladder carcinomas from workers exposed to aromatic amines. (A) Case
14/1 showing a mutation at codon 28 (GTG---ATG, valine to methionine).
(B) Case 26/1 showing a mutation at codon 110 (TGG-*TGA, tryptophane to
Stop). The sequence of the non-transcribed strand is shown with a C->T
mutation
sequencing. In parallel, p53 protein expression was analysed by
immunohistochemistry using the rabbit antibody CM-i. The data
on p53 analysis are summarized in Table 2. p53 mutations were
found in eight patients (38%). One patient (31/1) had two indepen-
dent mutations in the p513 coding sequence (codons 192 and 214),
and another (21/1) had a silent mutation at codon 231 that does
not correspond to a known polymorphism. This mutant allele
coexisted with the wild-type allele in the tumour tissue, suggesting
that the mutation is heterozygous. Non-neoplastic tissue from this
patient was not available. In addition, one patient (28/1) was
homozygous for a well-described polymorphism at codon 213
(CGA to CGG, silent). Four of the nine mutations were in exon 8,
at codons 276, 282 and 273 (two mutations). Other mutations were
in exon 7 (codons 231 and 242), exon 6 (codon 214), exon 5
(codon 192) and exon4(codon 117).
All of these mutations occurred at G:C base pairs. Six of them
were C to T transitions, including one at a CpG dinucleotide
(codon 282, CGG to TGG, patient 29/1). The other three mutations
were G to T transversions. Interestingly, the two mutations at
codon 273 were G to T transversions (CGT to CTT, Arg to Leu),
which represent only 9% of all the mutations at codon 273
described in thep53 mutation database (Hainaut et al, 1997).
Table 2 also shows that the frequency of p.53 mutations
increases with tumour grade and that the presence of a mutation is
generally associated with nuclear accumulation of the p53 protein.
However, nuclear p513 accumulation was also found in three
tumours without detectable mutations in exons 5-8 (patient 19/1,
GC to TA
11 Q0/
Insertions/
deletions
9.7%
AorT bases
15.5%
GC to AT
at CpG
15.2%
GC to AT
33.6%
Figure 2 Mutation spectrum of p53 in bladder cancers from the general
population (data from Hainaut et al, 1997)
grade 1; patient 8/1, grade 2; patient 25/1, grade 3) and, in one case
(patient 16/1), a mutation in exon 4 (codon 117, Gly to Glu) was
associated with cytoplasmic staining and nuclear exclusion of the
p53 protein (data not shown). MDM2 overexpression or amplifi-
cation has been reported in bladder cancers (Lianes et al, 1994),
and it is possible that inactivation and stabilization of the p53
protein derive from interaction with this cellular oncoprotein in
these tumours.
Associations between p53 mutation and exposure to
aromatic amines and tobacco
The subjects analysed were separated into several groups according
to their level ofoccupational ortobacco exposure. Foroccupational
exposure, we defined as 'high exposure' the group ofsubjects who
have been employed in the dye manufacturing industry for more
than 18 years, starting before 35 years ofage (nine cases). The 'low
exposure' group comprised individuals who have been employed
for less than 17 years, starting after 36 years of age (seven cases).
For exposure to tobacco, we compared the subjects reported as
'non-smokers' with the group of 'heavy smokers', defined as the
consumption of at least 180 cigarette packs per year for at least 10
years, without cessation before diagnosis.
Table 3 shows that the frequency of p53 mutations is higher
in both of the high-exposure groups than in the low-exposure
counterparts. Moreover, in each group, the frequency of mutation
increased with tumour grade. Of the four tumours from patients
who were highly exposed to both occupational aromatic amines
and tobacco, only one (patient 19/1) had no detectable p53 muta-
tion, but expressed high levels of histochemically detectable p53
protein. On the other hand, the two patients with grade 3 tumours
and no p53 mutations were non-smokers and of the low-
occupational-exposure group. Although the numbers in these
groups are small, these results suggest that the frequency ofp53
mutations increases with occupational and/or tobacco exposure.
Analysis ofp16, H-rasand p21
Sequencing ofexons 1 and 2 ofp]6 (plus flanking intronic splicing
sites) revealed three point mutations (Table 4), one ofthem being a
common polymorphism at codon 148 (Kelley et al, 1995; Smith-
S0rensen and Hovig, 1996). The two other mutations were in exon
1 (GTG to ATG, valine to methionine at codon 28) and exon 2
(TGG to TGA, tryptophane to stop at codon 110) (Figure 1).
Analysis by constant denaturing gel electrophoresis (CDGE)
revealed no mutation in exon 3 of p2JWAFI. However, immuno-
histochemical analysis of the expression of p21WAFI showed
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enormous variations from one tumour to another, with no signifi-
cant correlation with tumour grade or with p53 status (Table 2).
Only four tumours were negative for p21WAF) expression. Of the
seven tumours with missensep53 mutation, five were highly posi-
tive for p21WAF) expression and two were negative (tumour 31/1,
which contains two p53 mutations at codon 192 and 214, and
tumour 1/1-2, with a mutation at codon 273). Of ten cases with
normal bladder epithelium analysed as controls, none showed any
immunoreactivity. Thus, inactivation ofp53 by mutation does not
apparently result in the loss ofexpression of p21WAF), a transcrip-
tional target ofp53.
In this series ofbladder cancers, only one mutation was detected
in the H-ras gene at the first base ofcodon 61 in patient 6/1 (CAG
to AAG). A low prevalence of Ha-ras mutations (6%) was also
reported in bladder cancers from non-occupationally exposed
patients (Knowles et al, 1993).
DISCUSSION
Despite substantial epidemiological and experimental evidence for
the role of aromatic amines and tobacco carcinogens in the
aetiopathogenesis of bladder cancers, the exact nature of the
carcinogens involved in human bladder carcinogenesis is still
unclear. In this study, we have analysed the distribution of point
mutations in several cancer-related genes in a cohort of21 bladder
cancer patients with well-defined occupational exposure to
aromatic amines and for which information on tobacco consump-
tion was available.
Point mutations were found in p53 (nine mutations in eight
patients), pJ6MTSI (two somatic mutations) and H-ras (one muta-
tion), but not inp2JWAF). All these mutations occurred at G:C base
pairs, and eight of them were C to T transitions at non-CpG
dinucleotides; one was a C to T transition at a CpG dinucleotide.
The other three mutations were all G to T transversions in p53
(two at codon 273 and one at codon 192). The very low prevalence
of transitions at CpG dinucleotides, a type of mutation thought to
occur spontaneously by methylation and deamination ofcytosines,
suggests that endogenous mutagenic events do not play a major
role in the natural history of these cancers (Jones et al, 1991;
Greenblatt et al, 1994). Thus, the profile ofpoint mutations in the
bladder cancers analysed here is indicative of the involvement of
carcinogens of exogenous origin and is consistent with previous
observations in bladder cancers from occupationally exposed
patients (Taylor et al, 1996) or from patients exposed to tobacco
smoke (Spruck et al, 1993).
Mutations ofp53 at G:C base pairs are also frequent in bladder
cancers of the general population (Figure 2). Of the 310 bladder
cancers mutations listed in the January 1997 update of the p53
mutation database (Hainaut et al, 1997), 75% occur at G or C
bases, and about halfofthese are GC to AT transitions at non-CpG
sites. Transitions at CpG dinucleotides are infrequent (except in
squamous cell carcinomas of the bladder associated with schisto-
somiasis (Habuchi et al, 1993)). Although G to T transversions are
relatively rare (12%), 4 of the 12 mutations at codon 273, a
frequent site for CpG transitions in breast and colon cancers, are G
to T transversions (compared with 9% in all other cancers).
Several experimental studies have shownthat, after activation to
electrophilic metabolites, aromatic amines could bind covalently
to DNA. Aromatic amines bind preferentially at the C8 position
of guanine, although significant mutagenic activity was also
observed at certain A-T base pairs (Lasco et al, 1988; Essigmann
and Wood, 1993). Feeding mice with benzidine resulted in the
formation of hepatic N-(deoxyguanosin-8-yl)-N-acetylbenzidine
adducts, and N-(deoxyguanosin-8-yl)-4-aminobiphenyl was the
major adduct formed in the bladder of dogs fed with 4-ABP
(Talaska et al, 1990). This binding specificity is consistent with a
mutation mechanism affecting primarily G:C base pairs.
In experimental systems, the principal mutations induced by
aromatic amines are G to C and G to T transversions. G to T trans-
versions are also a typical molecular signature of the tobacco
carcinogen benzo(a)pyrene, and these mutations occur at high
frequency in lung cancers associated with tobacco smoking
(Denissenko et al, 1996). G to C transversions have been observed
in bladder cancers from smokers (Spruck et al, 1993), but it is
interesting to note that G to T transversions are not particularly
well represented in bladder cancers from occupationally exposed
patients (this study; Taylor et al, 1996) or from smokers (Spruck
et al, 1993). Instead, G:C to A:T transitions are the predominant
mutation type in both occupationally exposed patients and in
smokers. Although this observation suggests that similar carcino-
gens are responsible for bladder cancers in exposed workers and in
smokers, there is no direct evidence at this point that thep53 muta-
tions observed in bladder cancers are directly caused by aromatic
amines. Indeed, G to A transitions at non-CpG sites may result
from mutagenesis by other carcinogens, such as alkylating
nitrosamines or nitric oxide (Essigmann and Wood, 1993).
The absence of a specific p53 mutation pattern in exposed
workers raises the question of whether occupational exposure,
rather than environmental exposure and tobacco consumption, has
a significant role in the genesis ofbladder cancer. In this respect, it
is interesting to note that the frequency ofp53 mutation is higher
in the group of workers who have been exposed to aromatic
amines for a long time and at an early age (see Table 2). Although
a similar relationship also exists for tobacco consumption, it is
tempting to speculate that prolonged, occupational exposure may
result in an increased risk to acquire p53 mutations leading to
bladder cancer. As the number of cases involved in the present
study is small, this issue warrants further investigation to evaluate
with precision the adequacy of the protection measures presently
in force in the dye manufacturing industry.
Mutations of the other genes analysed in this study are appar-
ently infrequent in bladder cancer. In the case of p16, the occur-
rence of deletions of large segments of chromosome 9p is a
well-described genetic alteration, even in superficial bladder
cancer. Homozygous or heterozygous deletions of9p2l are some-
times detected in the early stages of bladder carcinogenesis. In
most cases, the deleted area encompasses the p16 locus
(Williamson et al, 1995). However, in cases with heterozygous
deletions, the remaining p16 allele is rarely inactivated by muta-
tion. Infrequent p16 mutations have been reported in bladder
cancer from non-occupationally exposed patients (Kai et al, 1995;
Packenham et al, 1995; Okajima et al, 1996). Furthermore, the
deleted area on chromosome 9 is usually large and also involves
several other well-characterized loci, including p15, interferon
alpha 1 (IFNA1), interferon beta 1 (IFNB1), methylthioadenosine
phosphorylase (MTAP) (Stadler et al, 1996; Zhang et al, 1996;
Balacz et al, 1997). Taken together, these data suggest that other
suppressor gene(s), in addition to p16, may be the target of dele-
tions on 9p in bladder cancers. In the case ofp21WAFI, it is remark-
able to note that the levels of protein expression were neither
correlated with those of p53 nor with p53 mutational status. This
discrepancy is however consistent with the notion that the p2JWAFI
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promoter can be transactivated by several distinct signalling path-
ways in addition to p53 (Sheikh et al, 1994; Zhang et al, 1995). In
addition, that most tumours show elevated levels of p21WAFI
suggests that in these cells p2lWAFJ is not capable of exerting its
suppressor effects and that the functioning of the cell cycle-
regulatory mechanisms may be altered through other pathways
not involving p21WAFI.
Several additional genetic alterations have been observed in
bladder cancers, involving allelic losses of various chromosomal
loci or chromosomal instability (Gonzalez-Zulueta et al, 1993;
Reznikoff et al, 1993; Knowles et al, 1994), as well as mutations
or altered expression ofdifferent genes, namely the retinoblastoma
gene (Miyamoto et al, 1995), MDM2 (Lianes et al, 1994), erbB-2
(Sauter et al, 1993), connexin (Grossman et al, 1994) and angio-
genic peptide basic fibroblast growth factor (Nguyen et al, 1993).
The temporal occurrence ofthese alterations is still not well under-
stood and the order in which these changes occur in the natural
history of bladder cancer may depend on the aetiology of this
cancer (Reznikoff et al, 1993; Lianes et al, 1994). Our results also
show that the frequency ofp53 mutation is closely associated with
tumour grade. This observation may be interpreted as being
indicative of a late involvement of p53 in bladder carcinogenesis
(Williamson et al, 1994; Vet et al, 1994). This is apparently in
contradiction with the interpretation ofthep53 mutation spectrum
as indicative of the involvement of exogenous carcinogens. One
explanation might be that these mutations may have been acquired
very early during carcinogenesis, but confer a significant selective
advantage in later stages on tumourprogression. It would therefore
be of great interest to use very sensitive detection methods to
investigate the presence ofp53 mutations in low-grade tumours, as
well as in the normal mucosa of exposed subjects and to follow
prospectively the biological behaviour ofthis genetic lesion.
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